NONMEM Users Network Archive

Hosted by Cognigen

RE: Generating TAD with ADDL dosing format

From: Pitsiu, Maria <Maria.Pitsiu>
Date: Tue, 20 Dec 2016 13:14:24 +0000

Hi Camila

If you don't have a lag time, use the following:
 IF(DOSTIM.NE.0.)DTIME=DOSTIM ; non-event dose times


If you have a lag time, use:

IF(DOSTIM>0.0) DTIME=DOSTIM -ALAG1 ; dostim is non-zero on =
additional doses (ADDL/II), no delay in doses
IF(AMT>0.AND.DOSTIM==0.0) DTIME=TIME ; for all dose events s=
cheduled explcitly in the data record, no delay

I hope this helps


Maria Pitsiu ICON Plc PK M&S 7122 3652 (internal) +44 162 849 3652 (externa=

From: owner-nmusers
 Behalf Of de Almeida, Camila
Sent: 20 December 2016 13:46
To: nmusers
Subject: [NMusers] Generating TAD with ADDL dosing format


I was wondering if I could get some guidance from this great group. My issu=
e is primarily with some diagnostic analysis, but this is taking me back to=
 an old NONMEM problem.

My aim is to run a VPC on a model I implemented, and if possible change the=
 idv to TAD instead of TIME. The reason for that is the VPC graph based on =
TIME looks dreadful as the data is sparse and from different studies of dif=
ferent lengths.

I'm having issues generating the TAD output column from my NONMEM run. I na=
ively assumed I could easily do that, but looking at the NONMEM archives it=
 seems this gets tricky when your dosing events are written using ADDL. Has=
 anyone ever managed to find a solution for this? And if not, is there an a=
lternative way to run the VCP on TAD, do we really need to get this column =
from NONMEM's output?

Thanks all,

Camila de Almeida, PhD
PKPD Scientist,
Modelling & Simulation, IMED Oncology DMPK
AstraZeneca UK Limited
R&D, Innovative Medicines

P Please consider the environment before printing this e-mail

AstraZeneca UK Limited is a company incorporated in England and Wales with =
registered number:03674842 and its registered office at 1 Francis Crick Ave=
nue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.
This e-mail and its attachments are intended for the above named recipient =
only and may contain confidential and privileged information. If they have =
come to you in error, you must not copy or show them to anyone; instead, pl=
ease reply to this e-mail, highlighting the error to the sender and then im=
mediately delete the message. For information about how AstraZeneca UK Limi=
ted and its affiliates may process information, personal data and monitor c=
ommunications, please see our privacy notice at<https:/=
/> <br /><br /> ICON plc made the following annotati=
ons. --------------------------------------------------------------------=
---------- This e-mail transmission may contain confidential or legally p=
rivileged information that is intended only for the individual or entity na=
med in the e-mail address. If you are not the intended recipient, you are=
 hereby notified that any disclosure, copying, distribution, or reliance up=
on the contents of this e-mail is strictly prohibited. If you have receiv=
ed this e-mail transmission in error, please reply to the sender, so that I=
CON plc can arrange for proper delivery, and then please delete the message=
. Thank You, ICON plc South County Business Park Leopardstown=

Received on Tue Dec 20 2016 - 08:14:24 EST

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to:

Once subscribed, you may contribute to the discussion by emailing: